School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
Department of Stomatology, Xi'an People's Hospital, Xi'an, Shaanxi, China.
Mol Oral Microbiol. 2021 Jun;36(3):192-201. doi: 10.1111/omi.12335. Epub 2021 Apr 12.
The dysregulation of immune system plays a crucial function in periodontitis development. Pro-inflammatory cytokines are thought to be critical for the generation and development of periodontitis. The enhanced activity of osteoclasts contributes to periodontitis pathogenesis. Nuclear factor-κB (NF-κB) signaling pathway directly enhances osteoclast differentiation and maturation. 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1) is a IκB kinases (IKK) inhibitor. This research aimed to investigate whether TPCA-1 had influence on the pathogenesis of chronic periodontitis. Mouse chronic periodontitis was induced by an in vivo ligature-induced periodontitis model. TPCA-1 was intravenously injected into mice after chronic periodontitis induction. Bone marrow-derived macrophages were cultured in macrophage colony-stimulating factor (M-CSF)-conditioned media with receptor activator of nuclear factor-kappa B ligand (RANKL) induce in vitro osteoclast differentiation. Western blot was used to analyze protein levels and mRNA levels were analyzed through qRT-PCR. TPCA-1 promoted osteoclastogenesis and osteoclast-related gene expression in vitro. The production of pro-inflammatory cytokines in osteoclasts induced by lipopolysaccharides was inhibited by TPCA-1 in vitro. In vitro TPCA-1 treatment inhibited Aggregatibacter actinomycetemcomitans (A.a)-induced expression of pro-inflammatory cytokines and NF-κB signal activation in osteoclasts. The induction of chronic periodontitis was inhibited by the absence of IKKb in mice. This research demonstrates that the treatment of TPCA-1 negatively regulates inflammation response and inhibits the osteoclastogenesis through the inactivation of NF-κB pathway in mouse chronic periodontitis model.
免疫系统的失调在牙周炎的发展中起着至关重要的作用。促炎细胞因子被认为是牙周炎发生和发展的关键。破骨细胞活性的增强有助于牙周炎的发病机制。核因子-κB(NF-κB)信号通路直接增强破骨细胞的分化和成熟。2-[(氨基羰基)氨基]-5-(4-氟苯基)-3-噻吩甲酰胺(TPCA-1)是一种 IκB 激酶(IKK)抑制剂。本研究旨在探讨 TPCA-1 是否对慢性牙周炎的发病机制有影响。通过体内结扎诱导牙周炎模型诱导小鼠慢性牙周炎。在慢性牙周炎诱导后,TPCA-1 通过静脉注射入小鼠体内。在巨噬细胞集落刺激因子(M-CSF)条件培养基中培养骨髓来源的巨噬细胞,并用核因子-kappa B 配体(RANKL)诱导体外破骨细胞分化。通过 Western blot 分析蛋白水平,通过 qRT-PCR 分析 mRNA 水平。TPCA-1 促进体外破骨细胞的生成和破骨细胞相关基因的表达。TPCA-1 抑制脂多糖诱导的破骨细胞中促炎细胞因子的产生。体外 TPCA-1 处理抑制 Aggregatibacter actinomycetemcomitans(A.a)诱导的破骨细胞中促炎细胞因子的表达和 NF-κB 信号的激活。在缺乏 IKKb 的小鼠中,慢性牙周炎的诱导受到抑制。本研究表明,在小鼠慢性牙周炎模型中,TPCA-1 通过失活 NF-κB 通路负调控炎症反应并抑制破骨细胞生成。